Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

ESC Congress

- PMLiVE

Regeneron agrees research collaboration with Parabilis Medicines

Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties

- PMLiVE

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

The treatment can be used to delay the onset of clinical type 1 diabetes

- PMLiVE

Sanofi announces positive results for venglustat in type 3 Gaucher disease

There are currently no approved treatments for the neurological symptoms of this disease

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Regeneron’s Libtayo receives EC approval for skin cancer

Phase 3 trial results showed the drug significantly improved disease-free survival

- PMLiVE

Amgen reports positive results from landmark cardiovascular study

The study found significant reductions of major cardiovascular events in high-risk adults following treatment

- PMLiVE

Sanofi reports improved patient outcomes from high-dose influenza vaccine

Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

- PMLiVE

Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

Sha joined Sanofi in 2019 and takes up her new role with immediate effect

- PMLiVE

Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

More than 180,000 people worldwide are diagnosed with the disease every year

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links